Cassava Sciences explores simufilam's potential for seizures in tuberous sclerosis. Results for Alzheimer's trials expected ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A. The intellectual property that Cassava has licensed is based on the promising research and development ...

“Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, in late first-quarter/early second ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A. “We are pleased to enter into a license agreement with Yale University, based on the research of Dr ...

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025 License agreement brings potential in a new ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A.

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025 License agreement brings potential in a new ...

Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A. “We are pleased to enter into a license agreement with Yale University, based on the research of Dr. Angélique ...